| Literature DB >> 32946774 |
James DeGregori1, Paul Pharoah2, Peter Sasieni3, Charles Swanton4.
Abstract
Screening leads to meaningful reductions in deaths from cancers. However, reductions in all-cause mortality (ACM) are harder to demonstrate. Failure to demonstrate ACM benefit should not diminish advances in cancer screening. We consider how co-morbidities related to an aging and damaged soma can hinder achievement of ACM benefit. CrownEntities:
Mesh：
Year: 2020 PMID： 32946774 DOI： 10.1016/j.ccell.2020.09.003
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743